Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer

Ras-targeted therapy represents a ‘holy grail’ in oncology. Based on our model prediction, Spiclomazine freezing the intermediate conformation of activated Ras is central to cancer therapeutics. We show here that Spiclomazine leads to an effective suppression in Ras-mediated signaling through abroga...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiaoyu, Zhao, Wenjing, Liu, Zuojia, Wang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805527/
https://www.ncbi.nlm.nih.gov/pubmed/29467941
http://dx.doi.org/10.18632/oncotarget.24025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805527/
https://www.ncbi.nlm.nih.gov/pubmed/29467941
http://dx.doi.org/10.18632/oncotarget.24025

Ejemplares similares